Skip Navigation LinksHome > April 2013 - Volume 32 - Issue 4 > Long-term Lopinavir/Ritonavir Monotherapy in HIV-infected Ch...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31827b1bd3
HIV Reports

Long-term Lopinavir/Ritonavir Monotherapy in HIV-infected Children

Kosalaraksa, Pope MD*; Ananworanich, Jintanat MD, PhD†‡§; Puthanakit, Thanyawee MD†¶; Pinyakorn, Suteeraporn MSc†§; Lumbiganon, Pagakrong MD*; Chuanjaroen, Thongsuai BNS; Chobkarjing, Umaporn MSc; Phanuphak, Praphan MD, PhD; Pancharoen, Chitsanu MD; Bunupuradah, Torsak MD; on behalf of the HIV-NAT 077 Study Team

Supplemental Author Material
Collapse Box


Background: Long-term data are limited on lopinavir/ritonavir monotherapy (mLPV/r) as a treatment simplification strategy in virologically suppressed children.

Methods: Children with confirmed plasma HIV viral load (VL) <50 copies/mL while receiving double protease inhibitors (dPI) were switched to mLPV/r therapy. Virologic failure (VF) was defined as 2 consecutive VL ≥ 500 or 3 consecutive VL ≥ 50 copies/mL. dPI was resumed within 4 weeks in children with VF. Primary endpoint was the proportion of children with VL < 50 copies/mL while still receiving mLPV/r at week 144.

Results: Forty children were enrolled; 90% were receiving LPV/r + saquinavir and 10% LPV/r + indinavir before simplifying to mLPV/r. Median age was 11.7 years; 50% were female. Median CD4% was 27%. Four (10%) had VL > 50 copies/mL at entry. At week 144, the proportion of children still receiving mLPV/r who had VL < 50 copies/mL was 22 of 40 (55%). The proportion of all children with VL < 50 copies/mL at week 144 was 33 of 40 (82.5%). Among 16 children who had VF and resumed dPI, 11 (69%) achieved VL < 50 copies/mL at week 144. No children with VF had major LPV/r mutations. Having detectable VL at entry and adherence by pill count <95% for >3 times at any visits during the study period significantly predicted VF on mLPV/r (both P = 0.025). The proportion of children with elevated total cholesterol (>200 mg/dL) decreased from 65% at baseline to 40% at week 144 (P = 0.007).

Conclusions: About half of children maintained virologic suppression on mLPV/r for almost 3 years. VF was common but the majority achieved suppression after resuming dPI and none had major LPV/r mutations. mLPV/r should only be considered for simplified maintenance therapy if frequent VL monitoring to detect VF is available.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.